Respiratory Infection

New Antibiotic Appears Safe With Low Resistance Susceptibility

Published in TB and Outbreaks Week, June 29th, 1998

Experts at the recently held 8th International Congress of Infectious Diseases (ICID) concluded that the increasing prevalence of resistance to traditional first-line agents among the most common respiratory pathogens poses a threat to patients whether they are treated in the hospital or at home.

For this reason, researchers are seeking new therapies that have a broader antibacterial spectrum of activity while maintaining a high safety profile.

Preliminary data presented at the meeting suggested that a new methoxyquinolone antibiotic, BAY 12-8039 (proposed name: moxifloxacin), might meet these criteria as it shows promise in the treatment of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1998-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry